Clinical Trial Update: Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and efficacy of intravitreal LFG316 in non-infectious intermediate, posterior, and panuveitis has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-infectious Intermediate Uveitis
• Non-infectious Panuveitis
• Non-infectious Posterior Uveitis

Drugs mentioned

• LFG316

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis | Phase 2 | Status: COMPLETED | Results posted: 2018-10-31